



# INTRODUCTION TO EXPERIMENTAL DESIGN AT CRUK-CI

CHANDRA CHILAMAKURI  
KAMAL KISHORE  
JING SU  
RORY STARK  
29 OCTOBER 2018

[tinyurl.com/cruk-edesign](https://tinyurl.com/cruk-edesign)

# Agenda

**WHY PERFORM EXPERIMENTS?**

**WHAT MAKES FOR A WELL DESIGNED EXPERIMENT?**

**KEY ASPECTS OF EXPERIMENTAL DESIGN**

- Experimental variables
- Power: variance and replicates
- Bias: confounding factors, randomisation, and controls

**DESIGN PARAMETERS**


**EXPERIMENTAL DESIGN PROCESS AT CRUK-CI**

**PRACTICALS**

# Why Perform Experiments?

# Reproducible Research

# Crisis in Reproducible Research



UNIVERSITY OF  
CAMBRIDGE

<http://neilfws.github.io/PubMed/pmretract/pmretract.html>

5



CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE

# 47 of 53 high-profile cancer studies were not reproducible!



NATURE | COMMENT



## Drug development: Raise standards for preclinical cancer research

**C. Glenn Begley & Lee M. Ellis**

**Affiliations | Corresponding author**

*Nature* **483**, 531–533 (29 March 2012) | doi:10.1038/483531a

Published online 28 March 2012

# Need for Good Design

# Consequences of Poor Experimental Design...

- **Cost** of experimentation. We have a responsibility to CRUK donors!
- **Limited & Precious** material, esp. clinical samples.
- **Immortalization** of data sets in public databases and methods in the literature. Our bad science begets more bad science.
- **Ethical concerns** of experimentation: animals and clinical samples.



# A Well-Designed Experiment:

## Should have

- CLEAR OBJECTIVES
- FOCUS AND SIMPLICITY
- SUFFICIENT POWER
- RANDOMISED COMPARISONS

## And be

- PRECISE
- UNBIASED
- AMENABLE TO STATISTICAL ANALYSIS
- REPRODUCIBLE



## Ronald A. Fisher(1890-1962)



*“TO CONSULT THE STATISTICIAN AFTER AN EXPERIMENT IS FINISHED IS OFTEN MERELY TO ASK HIM TO CONDUCT A POST MORTEM EXAMINATION. HE CAN PERHAPS SAY WHAT THE EXPERIMENT DIED OF.”*

*“... VERY OFTEN, ... THE MOST ELABORATE STATISTICAL REFINEMENTS POSSIBLE COULD INCREASE THE PRECISION BY ONLY A FEW PERCENT, YET A DIFFERENT DESIGN INVOLVING LITTLE OR NO ADDITIONAL EXPERIMENTAL LABOUR MIGHT INCREASE THE PRECISION TWO-FOLD, OR FIVE-FOLD OR EVEN MORE.”*

# Aspects of Experimental Design

- **EXPERIMENTAL FACTORS**
- **POWER**
  - Sources of Variance
  - Replicates
- **BIAS**
  - Confounding factors
  - Randomisation wherever a decision is to be made
    - Controls for both measured and unmeasured factors
  - Controls

# Experimental Factors

# Experimental Factors

## FACTORS: ASPECTS OF EXPERIMENT THAT CHANGE AND INFLUENCE THE OUTCOME OF THE EXPERIMENT


- e.g. time, weight, drug, gender, ethnicity, country, plate, cage etc.

## VARIABLE TYPE DEPENDS ON TYPE OF MEASUREMENT:

- Categorical (**nominal**) , e.g. gender
- Categorical with ordering (**ordinal**), e.g. tumour grade
- **Discrete**, e.g. shoe size, number of cells
- **Continuous**, e.g. body weight in kg, height in cm

## INDEPENDENT AND DEPENDENT VARIABLES

- Independent variable (IV): what you change
- Dependent variable (DV): what changes due to IV
- “**If** (**independent** variable), **then** (**dependent** variable)”



CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE

# Capturing Variance

# Sources of Variation

## BIOLOGICAL “NOISE”

- Biological processes are inherently stochastic
- Single cells, cell populations, individuals, organs, species....
- Timepoints, cell cycle, synchronized vs. unsynchronized

## TECHNICAL NOISE

- Reagents, antibodies, temperatures, pollution
- Platforms, runs, operators

**CONSIDER IN ADVANCE AND CONTROL**

***REPLICATION REQUIRED TO CAPTURE VARIANCE***



CANCER  
RESEARCH  
UK


CAMBRIDGE  
INSTITUTE

# Sample size and experimental power

## WHY DO YOU NEED REPLICATES?

## CALCULATING APPROPRIATE SAMPLE SIZES

- Power calculations
- Planning for precision
- Resource equation



## EXPERIMENTAL POWER

- **Power:** the **probability** of detecting an **effect** of a specified size if present.
  - Identify and control the **sources of variability**
  - Power calculations estimate sample size required to detect an effect *if degree of variability is known*
  - Using **appropriate numbers** of samples (sample size/replicates)
  - If adding samples increases variability, that alone won't add power!




# Types of Replication

## BIOLOGICAL REPLICATION:

- *In vivo*:
  - Patients
  - Mice
- *In vitro*:
  - Different cell lines
  - Re-growing cells (passages)


## TECHNICAL REPLICATION:

- Experimental protocol
- Measurement platform (i.e. sequencer)



# Precision, Accuracy, Confounders, and Bias

# Precision and Accuracy



CANCER  
RESEARCH  
UK


CAMBRIDGE  
INSTITUTE

# Confounding Factors

ALSO KNOWN AS EXTRANEOUS, HIDDEN, LURKING OR MASKING FACTORS,  
OR THE THIRD VARIABLE OR MEDIATOR VARIABLE.

MAY MASK AN ACTUAL ASSOCIATION OR FALSELY DEMONSTRATE AN APPARENT  
ASSOCIATION BETWEEN THE INDEPENDENT & DEPENDENT VARIABLES.

HYPOTHETICAL EXAMPLE WOULD BE A STUDY OF COFFEE DRINKING AND LUNG  
CANCER.



CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE

# Confounding Factors

## OTHER EXAMPLES:

- Democrats were less satisfied with their sex lives than Republicans.  
(ABC poll report).
- Overweight (not obese) people have longer life expectancy than thin people  
(US Centre for Disease Control).

**Science**express

Report

## Genetic Signatures of Exceptional Longevity in Humans

Paola Sebastiani,<sup>1\*</sup> Nadia Solovieff,<sup>1</sup> Annibale Puca,<sup>2</sup> Stephen W. Hartley,<sup>1</sup> Efthymia Melista,<sup>3</sup> Stacy Andersen,<sup>4</sup> Daniel A. Dworkis,<sup>3</sup> Jemma B. Wilk,<sup>5</sup> Richard H. Myers,<sup>5</sup> Martin H. Steinberg,<sup>6</sup> Monty Montano,<sup>3</sup> Clinton T. Baldwin,<sup>6,7</sup> Thomas T. Perls<sup>4\*</sup>

<sup>1</sup>Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA. <sup>2</sup>IRCCS Multimedica, Milano, Italy; Istituto di Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, Segrate, 20122, Italy. <sup>3</sup>Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA. <sup>4</sup>Section of Geriatrics, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA 02118, USA. <sup>5</sup>Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA. <sup>6</sup>Departments of Medicine and Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA 02118, USA. <sup>7</sup>Center for Human Genetics, Boston University School of Medicine, Boston, MA 02118, USA.

- **GWAS STUDY: 800 CENTENARIANS VS. CONTROLS**
- **FOUND 150 SNPS PREDICTING CENTENARIANS WITH 77 % ACCURACY**
- **PROBLEM: THEY USED DIFFERENT SNP CHIPS FOR CENTENARIANS AND CONTROLS**
- **RETRACTED IN 2011 FOLLOWING INDEPENDENT REVIEW AND QC OF DATA**

<http://www.the-scientist.com/blog/display/57558/>



CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE

# Solutions

## CONSIDER ALTERNATIVE EXPLANATIONS

### CONTROL TECHNICAL EFFECTS:


#### — Randomisation

- Statistical analyses assume randomised comparisons
- May not see issues caused by non-randomised comparisons
- Make every decision *random* not *arbitrary*
- Caveat: over-randomization can increase error

#### — Blinding

































































































- Especially important where subjective measurements are taken
- Potentially multiple degrees of blinding (*eg.* double-blinding)

# Technical Confounding Factors: Batch Effects



































































































RNA Extraction

Day1, Plate 1

|   | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A |    |    |    |    |    |    |    |    |    |    |    |    |
| B |    |    |    |    |    |    |    |    |    |    |    |    |
| C |    |    |    |    |    |    |    |    |    |    |    |    |
| D |    |    |    |    |    |    |    |    |    |    |    |    |
| E |    |    |    |    |    |    |    |    |    |    |    |    |
| F |   |   |   |   |   |   |   |   |   |   |   |   |
| G |  |  |  |  |  |  |  |  |  |  |  |  |
| H |  |  |  |  |  |  |  |  |  |  |  |  |

































































































Control

Day2, Plate 2

|   | 1   | 2  | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  |
|---|---|--|---|---|---|---|---|---|---|---|---|---|
| A |    |    |    |    |    |    |    |    |    |    |    |    |
| B |    |    |    |    |    |    |    |    |    |    |    |    |
| C |    |    |    |    |    |    |    |    |    |    |    |    |
| D |    |    |    |    |    |    |    |    |    |    |    |    |
| E |    |    |    |    |    |    |    |    |    |    |    |    |
| F |   |   |   |   |   |   |   |   |   |   |   |   |
| G |  |  |  |  |  |  |  |  |  |  |  |  |
| H |  |  |  |  |  |  |  |  |  |  |  |  |

Treatment 1

Day3, Plate 3

|   | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A |    |    |    |    |    |    |    |    |    |    |    |    |
| B |    |    |    |    |    |    |    |    |    |    |    |    |
| C |    |    |    |    |    |    |    |    |    |    |    |    |
| D |    |    |    |    |    |    |    |    |    |    |    |    |
| E |    |    |    |    |    |    |    |    |    |    |    |    |
| F |   |   |   |   |   |   |   |   |   |   |   |   |
| G |  |  |  |  |  |  |  |  |  |  |  |  |
| H |  |  |  |  |  |  |  |  |  |  |  |  |

Treatment 2

The difference between Control, Treatment 1 and Treatment 2 is confounded by **day** and **plate**.




CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE



# Randomised Block Design

**Blocking** is the arranging of *experimental units* in groups (blocks) that are similar to one another.



RBD across plates so that each plate contains spatially randomised **equal proportions** of:

- Control
- Treatment 1
- Treatment 2


controlling plate effects.

# Randomised Block Design

**Good** design example: Alzheimer's study from GlaxoSmithKline


## Plate effects by plate

Left PCA plot show *large plate effects*.  
Each colour corresponds to a different plate



## Plate effects by case/control

Right PCA plot shows each plate cluster contains *equal proportions* of cases (blue) and controls (green).



# Experimental Controls

# Experimental Controls

## CONTROLLING ERRORS

- Type I: FP
  - Negative controls: should have minimal or no effect
- Type II: FN
  - Positive controls: known effect

## TECHNICAL CONTROLS

- Detect/correct technical biases
- Normalise measurements (quantification)

# Examples of Experimental Controls

- WILD-TYPE ORGANISM (KNOCKOUTS)
- INACTIVE siRNA (SILENCING)
- VEHICLE (TREATMENTS)
- INPUT: FRAGMENTED CHROMATIN (ChIP)
- SPIKE-INS (QUANTIFICATION/NORMALISATION)
- “GOLD STANDARD” DATAPOINTS
- MULTI-LEVEL CONTROLS
  - e.g. contrast Vehicle/Input vs. Treatment/Input



CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE

# Design Parameters for Sequencing Experiments



# Design Issues: Sequencing Experiments

## PLATFORMS

## LIBRARY PREPS

## MULTIPLEXING AND POOLING STRATEGIES

## SINGLE-END VS PAIRED END

## SEQUENCING DEPTH

- Coverage
- Lanes

## VALIDATION

- Knock-downs
- Pull-downs



CANCER  
RESEARCH  
UK

CAMBRIDGE  
INSTITUTE

# Experimental Design process at CRUK-CI



# CRUK-CI Experimental Design Process

- Students required to take (this) Experimental Design class
- All sequencing and proteomics experiments require experimental design review meeting
  - Simple form with key aspects of experiment
  - Attended by Scientists, Genomics/Proteomics Core, Bioinformatics Core, Statistician
  - Project opened in LIMS afterwards
- Randomisation and Layouts
  - Checkpoint for experiment
  - Project cleared for sample submission
- Keys:
  - Form and meeting not onerous
  - (Currently) not chargeable
  - Scientists agree process improves experiments!



# Experimental Design Meetings - Genomics

TUESDAY 30 MIN SLOTS (2:00-3:00PM) WITH BIOINFORMATICS GENOMICS/PROTEOMICS CORES

## REQUIREMENTS:

- Email [CRIExperimentalDesign@cruk.cam.ac.uk](mailto:CRIExperimentalDesign@cruk.cam.ac.uk) to request meeting
- Fill in [Experimental Design Form](#) and return 1 week prior to meeting
- **Your attendance**
- Provide **project background** (a few slides from you)

## DISCUSSION:

- Planning, time-scale, cost, aims, scope, questions
- Choosing the correct technology
- Effect size & Sample-size calculation?
- Sample collection and processing methods
- Sample information (meta-data) collection
- Randomisation, Blocking and Replication issues
- Technical issues e.g. what sequencing depth?
- Will Bioinformatics Core help with/do analysis?
- Analysis deliverables



# Experimental Design Meetings - Proteomics

TUESDAY 30 MIN SLOTS (2:00-3:00PM) WITH BIOINFORMATICS GENOMICS/PROTEOMICS CORES

## REQUIREMENTS:

- Email [ProteomicsProjectDesign@cruk.cam.ac.uk](mailto:ProteomicsProjectDesign@cruk.cam.ac.uk) to request meeting
- Fill in [ProteomicsMetadataTemplate.xls](#) **Your attendance**
- Provide **project background** (a few slides from you)

## DISCUSSION:

- Planning, time-scale, cost, aims, scope, questions
- Choosing the correct technology
- Effect size & Sample-size calculation?
- Sample collection and processing methods
- Sample information (meta-data) collection
- Randomisation, Blocking and Replication issues
- Technical issues e.g. what sequencing depth?
- Will Bioinformatics Core help with/do analysis?
- Analysis deliverables



# Experimental Design Guide

- [HTTPS://SHAREPOINT.CRI.CAMRES.ORG/SITES/BIOINFORMATICS/  
PUBLIC/INTRODUCTIONTOEXPERIMENTALDESIGN/  
EXPERIMENTALDESIGNMANUAL.PDF](https://sharepoint.cri.camres.org/sites/bioinformatics/public/introductiontoexperimentaldesign/experimentaldesignmanual.pdf)
- [TINYURL.COM/CRUK-EDESIGN](https://tinyurl.com/cruk-edesign)



# Practicals

1. **Genomic/Clinical**: Identification of prognostic biomarkers in human prostate cancer patients ([Rory](#))
2. **RNA-seq/Animal**: Effects of mutant vs wildtype HHEX in liver and brain development ([Jing](#))
3. **ChIP-seq/Cultured Cells**: Transcription factor binding divergence in mice ([Chandu](#))
4. **Quantitative Proteomics/Cultured Cells**: AR interactome differences between drug responsive/resistant conditions ([Kamal](#))

